Exelixis Competitors and Similar CompaniesClear all

Exelixis's competitors and similar companies include Deciphera Pharmaceuticals, Genocea Biosciences, Northwest Biotherapeutics and Glactone Pharma.
Exelixis
Exelixis
Exelixis is an oncology company that develops cancer treatments.
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
Genocea Biosciences
Genocea Biosciences
Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer.
Northwest Biotherapeutics
Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing and commercializing immunotherapy products to treat cancer.
Glactone Pharma
Glactone Pharma
Glactone Pharma is a biotech company. It develops a pipeline of STAT3 inhibitors for the use in immuno-oncology and for the treatment of drug-resistant cancers.
Founding Date
Founding Date
1994
Founding Date
2003
Founding Date
2006
Founding Date
1998
Founding Date
2012
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Alameda, US HQ
Locations
Waltham, US HQ
Lawrence, US
Locations
Cambridge, US HQ
Locations
Bethesda, US HQ
Locations
Helsingborg, SE HQ
Employees
Employees
1,14712% decrease
Employees
35037% increase
Employees
593% decrease
Employees
1721% increase
Employees
6
Valuation ($)
Valuation ($)
8.2 b
Valuation ($)
2.2 b
Valuation ($)
5.7 k
Valuation ($)
349.5 m
Valuation ($)
N/A

Financial

Revenue (est.)
Revenue (est.)
$2.2b (FY, 2024)
Revenue (est.)
$163.4m (FY, 2023)
Revenue (est.)
$1.6m (FY, 2021)
Revenue (est.)
$1.4m (FY, 2024)
Revenue (est.)
N/A
Cost of goods
Cost of goods
$76.2m (FY, 2024)
Cost of goods
$3.7m (FY, 2023)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$2.1b (FY, 2024)
Gross profit
$159.6m (FY, 2023)
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Net income
Net income
$521.3m (FY, 2024)
Net income
($194.9m) (FY, 2023)
Net income
($33.2m) (FY, 2021)
Net income
($83.8m) (FY, 2024)
Net income
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 714m
Total funding raised
$ 209.5m
Total funding raised
$ 135.9m
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Deciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.

View company
Genocea Biosciences
HQ
Cambridge, US
Employees
59↓ 3% decrease

Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer.

View company
Northwest Biotherapeutics
HQ
Bethesda, US
Employees
17↑ 21% increase

Northwest Biotherapeutics is a biotechnology company focused on developing and commercializing immunotherapy products to treat cancer.

View company
Glactone Pharma
HQ
Helsingborg, SE

Glactone Pharma is a biotech company. It develops a pipeline of STAT3 inhibitors for the use in immuno-oncology and for the treatment of drug-resistant cancers.

View company